| Bioactivity | MAX-40279 is a dual and potent inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 has the potential for the research of acute myelogenous leukemia (AML) (extracted from patent WO2021180032)[1]. | |||||||||
| Target | FLT3 and FGFR | |||||||||
| Name | MAX-40279 | |||||||||
| CAS | 2070931-57-4 | |||||||||
| Formula | C22H23FN6OS | |||||||||
| Molar Mass | 438.52 | |||||||||
| Appearance | Solid | |||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | |||||||||
| Storage |
|
|||||||||
| Reference | [1]. Yuguang Wang, et al. Novel Therapeutic Methods. Patent WO2021180032A1. |
MAX-40279
CAS: 2070931-57-4 F: C22H23FN6OS W: 438.52
MAX-40279 is a dual and potent inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 has the potential for the research of
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.